Human papillomavirus vaccine formulations
US6251678A · kind A · utility
41Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 2, 2000 |
| Grant date | Jun 26, 2001 |
| Priority date | — |
| Expiry date | Feb 2, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/108331
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
New human papilloma virus (HPV) vaccine formulations exhibit enhanced long-term stability. Formulation components can include: virus-like particles (VLPs) absorbed onto aluminum, a salt, non-ionic surfactant, and a buffer. Additional formulations also contain a polymeric polyanionic stabilizer and a salt either in the presence or absence buffering agents and nonionic detergent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.